ZA200401073B - Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as PPAR activators. - Google Patents

Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as PPAR activators. Download PDF

Info

Publication number: ZA200401073B
Authority: ZA; South Africa
Prior art keywords: alkyl; compounds; preparing; medicament; treatment
Prior art date: 2001-08-31

Application number

ZA200401073A

Other languages

English (en)

Inventor

Heiner Glombik

Eugen Falk

Wendelin Frick

Stefanie Keil

Hans-Ludwig Schaefer

Lothar Schwink

Wolfgang Wendler

Original Assignee

Aventis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-31

Filing date

2004-02-10

Publication date

2004-08-26

2004-02-10 Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh

2004-08-26 Publication of ZA200401073B publication Critical patent/ZA200401073B/en

Links

238000004519 manufacturing process Methods 0.000 title claims description 5
239000012190 activator Substances 0.000 title description 2
102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 title 1
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 title 1
150000001875 compounds Chemical class 0.000 claims description 78
125000004432 carbon atom Chemical group C* 0.000 claims description 20
125000004430 oxygen atom Chemical group O* 0.000 claims description 20
125000000217 alkyl group Chemical group 0.000 claims description 16
239000003814 drug Substances 0.000 claims description 16
150000003839 salts Chemical class 0.000 claims description 16
239000000203 mixture Substances 0.000 claims description 12
238000002156 mixing Methods 0.000 claims description 5
125000000392 cycloalkenyl group Chemical group 0.000 claims description 4
125000000753 cycloalkyl group Chemical group 0.000 claims description 4
206010012601 diabetes mellitus Diseases 0.000 claims description 4
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 4
208000011580 syndromic disease Diseases 0.000 claims description 3
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
208000035475 disorder Diseases 0.000 claims 2
230000037356 lipid metabolism Effects 0.000 claims 2
208000024827 Alzheimer disease Diseases 0.000 claims 1
201000001320 Atherosclerosis Diseases 0.000 claims 1
208000031229 Cardiomyopathies Diseases 0.000 claims 1
208000030814 Eating disease Diseases 0.000 claims 1
208000019454 Feeding and Eating disease Diseases 0.000 claims 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
206010019280 Heart failures Diseases 0.000 claims 1
206010061218 Inflammation Diseases 0.000 claims 1
208000008589 Obesity Diseases 0.000 claims 1
208000001132 Osteoporosis Diseases 0.000 claims 1
235000014632 disordered eating Nutrition 0.000 claims 1
239000008103 glucose Substances 0.000 claims 1
230000004054 inflammatory process Effects 0.000 claims 1
235000020824 obesity Nutrition 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 description 8
-1 hydrochloric acid Chemical class 0.000 description 7
239000003826 tablet Substances 0.000 description 6
238000002360 preparation method Methods 0.000 description 5
238000009472 formulation Methods 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
239000007788 liquid Substances 0.000 description 4
239000000843 powder Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
239000000969 carrier Substances 0.000 description 3
239000008187 granular material Substances 0.000 description 3
238000000034 method Methods 0.000 description 3
239000000651 prodrug Substances 0.000 description 3
229940002612 prodrug Drugs 0.000 description 3
239000007787 solid Substances 0.000 description 3
244000215068 Acacia senegal Species 0.000 description 2
229920000084 Gum arabic Polymers 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
208000001145 Metabolic Syndrome Diseases 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
239000000205 acacia gum Substances 0.000 description 2
235000010489 acacia gum Nutrition 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
239000002585 base Substances 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000002775 capsule Substances 0.000 description 2
210000004051 gastric juice Anatomy 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000000465 moulding Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
208000032928 Dyslipidaemia Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
101150014691 PPARA gene Proteins 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
201000010390 abdominal obesity-metabolic syndrome 1 Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001447 alkali salts Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
229920006318 anionic polymer Polymers 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
244000309464 bull Species 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
230000023852 carbohydrate metabolic process Effects 0.000 description 1
235000021256 carbohydrate metabolism Nutrition 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003978 infusion fluid Substances 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
208000011661 metabolic syndrome X Diseases 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical compound C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000006072 paste Substances 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229940068917 polyethylene glycols Drugs 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
239000007762 w/o emulsion Substances 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Nutrition Science (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ZA200401073A 2001-08-31 2004-02-10 Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as PPAR activators. ZA200401073B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE10142734A DE10142734A1 (de)	2001-08-31	2001-08-31	Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Publications (1)

Publication Number	Publication Date
ZA200401073B true ZA200401073B (en)	2004-08-26

Family

ID=7697283

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200401073A ZA200401073B (en)	2001-08-31	2004-02-10	Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as PPAR activators.

Country Status (3)

Country	Link
DE (1)	DE10142734A1 (es)
EC (1)	ECSP044994A (es)
ZA (1)	ZA200401073B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7223796B2 (en)	2002-04-11	2007-05-29	Sanofi-Aventis Deutschland Gmbh	Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use
US7078404B2 (en)	2002-04-11	2006-07-18	Sanofi-Aventis Deutschland Gmbh	Acyl-3-carboxyphenylurea derivatives, processes for preparing them and their use
US7262220B2 (en)	2002-07-11	2007-08-28	Sanofi-Aventis Deutschland Gmbh	Urea- and urethane-substituted acylureas, process for their preparation and their use
ATE452879T1 (de)	2002-07-12	2010-01-15	Sanofi Aventis Deutschland	Heterozyklisch substituierte benzoylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US20040157922A1 (en)	2002-10-04	2004-08-12	Aventis Pharma Deutschland Gmbh	Carboxyalkoxy-substituted acyl-carboxyphenylurea derivatives and their use as medicaments
DE10306250A1 (de)	2003-02-14	2004-09-09	Aventis Pharma Deutschland Gmbh	Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308353A1 (de) *	2003-02-27	2004-12-02	Aventis Pharma Deutschland Gmbh	Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7008957B2 (en)	2003-07-25	2006-03-07	Sanofi-Aventis Deutschland Gmbh	Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
US7094800B2 (en)	2003-07-25	2006-08-22	Sanofi-Aventis Deutschland Gmbh	Cyanopyrrolidides, process for their preparation and their use as medicaments
WO2005026134A1 (en) *	2003-09-17	2005-03-24	Novartis Ag	Organic compounds
US7498341B2 (en)	2004-01-31	2009-03-03	Sanofi Aventis Deutschland Gmbh	Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7402674B2 (en)	2004-01-31	2008-07-22	Sanofi-Aventis Deutschland Gmbh,	7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
DE102004026532A1 (de) *	2004-05-29	2006-01-05	Sanofi-Aventis Deutschland Gmbh	Substituierte Oxazol-Benzoisothiazoldioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
BRPI0715160A2 (pt)	2006-08-08	2013-06-11	Sanofi Aventis	imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
DE102007005045B4 (de)	2007-01-26	2008-12-18	Sanofi-Aventis	Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2012120050A1 (de)	2011-03-08	2012-09-13	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683703B1 (de)	2011-03-08	2015-05-27	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8809325B2 (en)	2011-03-08	2014-08-19	Sanofi	Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
WO2012120058A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung

2001
- 2001-08-31 DE DE10142734A patent/DE10142734A1/de not_active Ceased
2004
- 2004-02-10 ZA ZA200401073A patent/ZA200401073B/en unknown
- 2004-02-27 EC EC2004004994A patent/ECSP044994A/es unknown

Also Published As

Publication number	Publication date
ECSP044994A (es)	2004-04-28
DE10142734A1 (de)	2003-03-27

Publication	Publication Date	Title
ZA200409779B (en)	2006-06-28	Novel thiophenylglycoside derivatives, methods for production thereof, medicaments comprising said compounds and use thereof
KR100567608B1 (ko)	2006-04-04	메트포르민과 피브레이트의 조합물로 이루어진 약학조성물, 및 과혈당증 저하용 약제의 제조 용도
EP2278960B2 (en)	2019-11-13	Dosing regimen for a selective sip1 receptor agonist
EP2101772B1 (en)	2012-04-25	Intermediate duration neuromuscular blocking agents and antagonists thereof
ZA200501757B (en)	2005-09-07	Novel bicyclic inhibitors of hormone sensitive lipase.
CN1434796A (zh)	2003-08-06	酰基苯基脲衍生物,其制备方法和作为药物的用途
ES2435620T3 (es)	2013-12-20	Triacetil-3-hidroxifeniladenosina y su uso para regular la grasa en sangre
ZA200505763B (en)	2006-05-31	Diarylcycloalkyl derivatives, method for their production and their use as medicaments
WO2011025270A2 (ko)	2011-03-03	메트포르민 카페익산염, 그의 제조방법, 그를 포함하는 약학조성물 및 그를 포함하는 복합제제
EP2941242B1 (en)	2017-02-01	Injectable depot formulation comprising optically active tolvaptan and process of producing the same
SG174032A1 (en)	2011-09-29	Derivatives of 4-trimethylammonium-3-aminobutyrate and 4-trimethylphosphonium-3-aminobutyrate as cpt-inhibitors
ZA200505765B (en)	2006-05-31	4(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivatives and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis
EP1749539A2 (en)	2007-02-07	Preventives or remedies for fatty liver
US6399658B1 (en)	2002-06-04	Composition containing ascorbic acid
JPH0232093A (ja)	1990-02-01	抗レトロウィルスジフルオロ化ヌクレオシド類
ZA200106199B (en)	2002-03-06	Utilization of polycyclic 2-amino-thiazole systems in the production of medicaments for prophylaxis or treatment of obesity.
ZA200505761B (en)	2006-05-31	1,3,-substituted cycloalkyl derivatives containing acidic, mainly heterocyclic groups, corresponding production method and use of said derivatives as medicaments
ZA200106439B (en)	2002-03-06	Use of polycyclic thiazole systems for producing medicaments for preventing or treating obesity.
MXPA02001740A (es)	2002-08-06	Uso de bis-sulfonamidas para producir medicinas para la profilaxis o tratamiento de hiperlipidemia.
ZA200505766B (en)	2006-05-31	Cycloalkyl-substituted alkanoic acid derivatives methods for the production thereof and use thereof as a medicament
EP0471388B1 (de)	1993-07-14	Mittel zur Behandlung der Herzinsuffizienz
KR20040058266A (ko)	2004-07-03	메트포르민 및 4-옥소부탄산의 조합물을 포함하여이루어지는 약제학적 조성물 및 당뇨병을 치료하기 위한이의 용도
DE102005031575A1 (de)	2007-01-11	Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Förderung der Wundheilung
HUP0203790A2 (hu)	2003-04-28	(6-Metoxi-2-naftil)-ecetsav prodrugokat tartalmazó gyógyszerkészítmények alkalmazása gyulladás kezelésére
AU2004236596B2 (en)	2010-03-11	Use of phenoxyacetic acid derivatives for treating hyperactive bladder